Community Trust & Investment Co. Sells 6,865 Shares of CVS Health Corporation $CVS

Community Trust & Investment Co. decreased its position in shares of CVS Health Corporation (NYSE:CVS) by 2.7% during the 2nd quarter, HoldingsChannel reports. The fund owned 245,183 shares of the pharmacy operator’s stock after selling 6,865 shares during the period. CVS Health comprises approximately 1.3% of Community Trust & Investment Co.’s portfolio, making the stock its 22nd largest holding. Community Trust & Investment Co.’s holdings in CVS Health were worth $25,364,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of CVS. Vanguard Group Inc. raised its position in CVS Health by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock valued at $9,579,508,000 after purchasing an additional 1,824,424 shares during the last quarter. State Street Corp increased its stake in shares of CVS Health by 2.1% in the fourth quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock valued at $4,776,182,000 after buying an additional 1,245,457 shares during the period. Capital International Investors increased its stake in shares of CVS Health by 3.4% in the fourth quarter. Capital International Investors now owns 27,592,356 shares of the pharmacy operator’s stock valued at $2,189,793,000 after buying an additional 900,153 shares during the period. Norges Bank bought a new position in CVS Health in the 4th quarter valued at approximately $1,666,265,000. Finally, Morgan Stanley boosted its position in CVS Health by 6.3% during the 4th quarter. Morgan Stanley now owns 20,373,774 shares of the pharmacy operator’s stock worth $1,616,863,000 after buying an additional 1,211,631 shares during the period. Institutional investors and hedge funds own 80.66% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on CVS. JPMorgan Chase & Co. boosted their target price on shares of CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of CVS Health from $88.00 to $92.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Mizuho increased their price objective on CVS Health from $110.00 to $115.00 and gave the company an “outperform” rating in a report on Monday, June 8th. Piper Sandler reaffirmed an “overweight” rating and set a $113.00 target price on shares of CVS Health in a research report on Monday, June 1st. Finally, UBS Group lifted their target price on CVS Health from $122.00 to $126.00 and gave the stock a “buy” rating in a report on Thursday. Twenty-two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $106.46.

Insider Buying and Selling

In other CVS Health news, Director Larry Robbins sold 370,462 shares of CVS Health stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the sale, the director directly owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. The trade was a 7.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 3,372,000 shares of company stock worth $317,473,598 over the last ninety days. Company insiders own 0.85% of the company’s stock.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS reported second-quarter adjusted earnings of $2.58 per share, well above the $1.87 analyst consensus, while revenue rose 7.3% year over year to $106.1 billion. Management raised its 2026 adjusted EPS outlook to $7.90–$8.10, supported by improving performance at Aetna and strength in the retail business. CVS Health earnings and GLP-1 partnership article
• Positive Sentiment: The company expanded its collaboration with Eli Lilly on GLP-1 weight-management treatments. The initiative could help CVS combine its pharmacy, insurance and care-delivery assets to capture a larger role in the growing obesity-treatment market. CVS GLP-1 strategy article
• Positive Sentiment: Analysts have modestly increased their fair-value estimate for CVS from $111.92 to $114.88, reflecting more constructive views following the earnings results, although execution and policy risks remain. CVS fair value estimate article
• Neutral Sentiment: Healthcare was among the sectors receiving defensive ETF inflows, which may provide some broader investor support for CVS, but the flows were concentrated largely in broad-market funds, Treasuries and gold rather than being a company-specific catalyst. Weekly ETF flows article
• Negative Sentiment: Executives warned that Caremark pharmacy-benefit-management membership could decline in 2026 and that changes involving the 340B drug-pricing program may remain a headwind into 2027. These comments overshadowed the earnings beat and guidance increase by raising concerns about future revenue and profit growth. CVS earnings call risks article

CVS Health Trading Down 0.6%

CVS opened at $95.61 on Friday. CVS Health Corporation has a twelve month low of $63.30 and a twelve month high of $110.68. The company has a fifty day moving average of $102.26 and a 200-day moving average of $87.74. The stock has a market cap of $122.28 billion, a PE ratio of 25.29, a price-to-earnings-growth ratio of 0.87 and a beta of 0.61. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.71. The business had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. CVS Health’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, sell-side analysts predict that CVS Health Corporation will post 8.03 EPS for the current year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were given a dividend of $0.665 per share. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 annualized dividend and a dividend yield of 2.8%. CVS Health’s dividend payout ratio is presently 70.37%.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.